BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk | Heart

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Editorial

BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: White HD

BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk

Heart 2022;108:1250-1252.